|Arena Pharmaceuticals, Inc.|
6154 Nancy Ridge Drive
United States - Map
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The companys products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.
|Arena Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 2. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 3; Compensation: 3.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Jack Lief Ph.D.,
Co-Founder, Chairman, Chief Exec. Officer and Pres
|Dr. Dominic P. Behan Ph.D., D.Sc.,
Co-Founder, Exec. VP, Chief Scientific Officer, Director and Member of Science Committee
|Mr. Robert E. Hoffman CPA,
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin.
|Mr. Steven W. Spector J.D.,
Exec. VP, Gen. Counsel and Sec.
|Dr. William R. Shanahan Jr., M.D., J.D.,
Chief Medical Officer and Sr. VP
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|